as not having achieved HbA1c control. We did planned  interim analyses at weeks 26 and 84.4,8 This trial is registered with ClinicalTrials.gov, number  NCT00641056. Role of the funding source The sponsors of the study were involved in study design, protocol development, data collection, data analysis, data interpretation, and writing of the report. All authors had full access to all the data in the study and had ﬁ  nal  responsibility for the decision to submit for publication. Results 456 patients were randomly assigned and received at least one dose of assigned drug, and so were included in the primary eﬃ   cacy analysis (mITT population; ﬁ  gure 1).   287 patients  (140 given exenatide and 147 given glargine) were included in the completer analysis. We recorded no substantial diﬀ  erences in baseline characteristics  between the mITT and completer populations (table 1). Various concomitant glucose-lowering drugs were used in both groups (appendix).